A New Generation of Biomarkers for Detecting Early Signs of Kidney Damage

Nephrotoxicity is a major problem in the preclinical and clinical setting that results in the failure of candidate compounds throughout the drug-development cycle. An article in this month’s GEN outlines the development of a new generation of biomarkers for drug-induced toxicity that provides greater sensitivity and earlier detection than previous methods. https://www.genengnews.com/gen-articles/fighting-kidney-toxicity-the-case-for-better-biomarkers/5178/

The Need for Additional Translational Biomarkers

The authors of this paper review the various methods of safety biomarker discovery and development, and challenge researchers to advance the use of safety biomarkers that are indicative of drug-induced toxicity. This type of research typically spans both preclinical and clinical development programs. Having the ability to identify translational safety biomarkers on the same technology platform is one of Myriad RBM’s strengths. Read the Paper Here

Urinary Biomarkers of Lupus Nephritis

Researchers at the University of Cincinnati College of Medicine, Ohio State University, and Johns Hopkins have identified several biomarkers of early kidney damage in patients suffering from lupus. Various combinations of the markers, including neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemotactic protein 1 (MCP-1), along with more traditional kidney markers, were able to accurately predict renal biopsy scores and disease outcome. Using these markers to measure clinical endpoints offers hope for noninvasive methods of monitoring the progression of lupus nephritis.
1 2